Log in to your Inderes Free account to see all free content on this page.
Swedish Orphan Biovitrum
376.60 SEK
-1.21 %
Less than 1K followers
SOBI
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Income statement
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Swedish Orphan Biovitrum
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | 14,248.0 | 15,261.0 | 15,529.0 | 18,790.0 | 22,123.0 | 26,027.0 | 28,238.0 |
| growth-% | 7.1 % | 1.8 % | 21.0 % | 17.7 % | 17.6 % | 8.5 % | |
| EBITDA | 5,934.0 | 6,841.0 | 5,739.0 | 6,232.0 | 7,266.0 | 9,304.0 | 10,963.0 |
| EBIT | 4,533.0 | 4,818.0 | 3,733.0 | 3,813.0 | 4,066.0 | 5,625.0 | 867.0 |
| Profit before taxes | 4,247.0 | 4,217.0 | 3,295.0 | 3,321.0 | 2,954.0 | 4,407.0 | 34.0 |
| Net income | 3,304.0 | 3,245.0 | 2,679.0 | 2,638.0 | 2,409.0 | 3,879.0 | 476.0 |
| EPS | 10.78 | 10.53 | 8.69 | 8.52 | 7.47 | 11.37 | 1.39 |
| Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend ratio | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % |
Login required
This content is only available for logged in users
Profitability and return on capital
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| EBITDA-% | 41.6 % | 44.8 % | 37.0 % | 33.2 % | 32.8 % | 35.7 % | 38.8 % |
| EBIT-% | 31.8 % | 31.6 % | 24.0 % | 20.3 % | 18.4 % | 21.6 % | 3.1 % |
| ROE | 19.5 % | 16.1 % | 11.5 % | 9.9 % | 7.1 % | 9.6 % | 1.3 % |
| ROI | 7.2 % | 6.7 % | 5.5 % | 5.0 % | 3.3 % | 5.1 % | 0.7 % |
Login required
This content is only available for logged in users